Australian biotech market watch 02/11/09
Monday, 02 November, 2009
Biotechnology stocks have taken a hit today as the Australian stock exchange dropped 93 points on the back of a turbulent day on Wall St and falling commodity prices.
Health stocks, as measured by the S&P/ASX 200 Health Care index, fell by 100 points to 8,286, or 1.2%, which was better than the 2% of the overall market as of 2pm this afternoon.
Of the biggest losers was Cochlear (ASX:COH), which dropped $1.35, or 2.1%, to $62.75, although this follows a late rise in share price on Friday afternoon. CSL (ASX:CSL) also lost 36c to $31.14. ResMed (ASX:RMD) stayed relatively steady, up 3c to $5.48.
Vitamin maker, Blackmores (ASX:BKL), also took a dive, shedding 68c, or 3.3%, to $20.02, after seeing a 6.6% increase on Friday. The stock is still up 52% from January 2.
Biota Holdings (ASX:BTA), which experienced a meteoric rise earlier in the year has waned further since its high in mid October, falling 13c, or 4.6%, to $2.71.
Falls were also seen by Ansell (ASX:ANN), which fell 11c, and HealthScope (ASX:HSP), which lost 13c to $4.63.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
